CONCIERGE ONCOLOGY ADVISORY

Expert cancer guidance, wherever you are.

A concierge oncology advisory service providing specialist-led second opinions in hematology and oncology from U.S. board-certified physicians. Each case is reviewed by a dedicated specialist who delivers a structured written opinion within 48–72 hours, then reviews the findings with you directly through a secure video consultation.

Start Your Case Review Learn How It Works

Board-Certified Specialists

48–72 Hour Turnaround

Written Report + Video Consult

Secure & HIPAA Compliant

A cancer diagnosis often raises important questions

Navigating treatment options can be complex. An independent review can provide clarity when you need it most.

Is my diagnosis accurate?

Confirmation of pathology and staging to ensure your treatment plan is based on correct information.

Are there other treatment options?

Exploration of alternative therapies, targeted treatments, or newer protocols that may be appropriate.

Am I eligible for clinical trials?

Assessment of potential clinical trials that could offer access to cutting-edge therapies.

What does my genomic testing mean?

Interpretation of complex molecular and genetic test results and how they impact your care.

Cancer Clarity MD clinical team at reception

OUR APPROACH

Specialist-Led. Precisely Organized.

Every case is reviewed by a U.S. board-certified oncologist. Our proprietary system organizes your records so the physician can focus entirely on clinical analysis - not paperwork.

Intelligent Record Organization

Our proprietary AI system securely processes and organizes hundreds of pages of medical records, extracting key data points to create a comprehensive clinical timeline.

Specialist Interpretation

A U.S. board-certified oncologist reviews the organized data, applying their clinical expertise to analyze your specific case and treatment options.

Written Report

You receive a detailed, easy-to-understand written report outlining findings, answering your questions, and providing actionable insights.

ACCESS TO CARE

If You May Be Eligible, We Connect You.

Our review goes beyond analysis. If our specialists identify potential eligibility for specific treatments or trials, we provide guidance on accessing them.

Guidance on accessing specialized medications
Information on compassionate use programs
Identification of relevant clinical trials
Recommendations for specialized treatment centers

Our physicians have experience with protocols from leading institutions:

MD Anderson Memorial Sloan Kettering Mayo Clinic Cleveland Clinic Dana-Farber Johns Hopkins

THE PROCESS

How the Review Works

A streamlined, secure process designed to get you answers quickly.

Submit Your Records

Securely upload your medical documents through our encrypted HIPAA-compliant portal.

Pathology reports Imaging & scans Lab results Genomic testing Clinic notes

Case Assignment

Your case is matched to a board-certified hematology-oncology specialist with relevant expertise in your diagnosis type.

Expert Review

Your specialist conducts a thorough review of all submitted materials against current evidence-based guidelines and the latest oncology literature.

NCCN Guidelines ASCO Updates ASH Presentations ESMO Guidelines Clinical Trials

Written Report

Receive a detailed written second opinion within 48-72 hours of record confirmation - structured, clear, and actionable.

Video Consultation

Speak directly with the physician who reviewed your case. Discuss findings, ask questions, and leave with a clear path forward.

View Full Process Details

SAMPLE REPORTS

What You Receive

A clear, actionable report designed to help you and your primary oncologist make informed decisions.

Cancer Clarity MD.

Specialist Review Report · CCMD-2025-0311-CLF

Reviewing Physician:

Dr. Nikki Bajaj, MD

ABIM · Hematology & Medical Oncology

Patient

Catherine L., 55F

Diagnosis

NSCLC Adenocarcinoma

Stage

IIIA (T2bN2M0)

Case Summary

55-year-old female with stage IIIA NSCLC confirmed on bronchoscopic biopsy. Molecular profiling (Foundation One CDx) reveals KRAS G12C mutation and high PD-L1 expression (TPS 68%) with STK11 co-mutation. Patient questions appropriateness of proposed concurrent chemoradiation and whether molecular findings support treatment modification.

Key Molecular Findings

KRAS G12C - Detected

Actionable in 2nd-line setting (sotorasib / adagrasib). Document for future planning.

PD-L1 TPS 68% + STK11

STK11 co-mutation may attenuate immunotherapy response despite high PD-L1.

Specialist Recommendations

Proceed with concurrent cisplatin-based chemoradiation - consistent with NCCN Category 1 for unresectable stage IIIA.
Consolidation durvalumab (PACIFIC protocol) appropriate; treating team should counsel on STK11 prognostic implications.
Refer to comprehensive cancer center for clinical trial evaluation of KRAS G12C-directed and STK11-resistant strategies.

Cancer Clarity MD.

Specialist Review Report · CCMD-2025-0187-JMK

Reviewing Physician:

Dr. Nikki Bajaj, MD

ABIM · Hematology & Medical Oncology

Patient

James M., 61M

Diagnosis

DLBCL, GCB Subtype

IPI Score

High-Intermediate (3)

Case Summary

61-year-old male with newly diagnosed Diffuse Large B-Cell Lymphoma, germinal center B-cell subtype, confirmed on excisional lymph node biopsy. PET-CT demonstrates stage III disease with bulky mediastinal involvement. Patient and family seeking independent review of proposed R-CHOP regimen and whether intensified therapy or clinical trial enrollment is warranted given IPI score.

Key Findings

MYC / BCL2 FISH - Negative

Double-hit lymphoma excluded. Standard R-CHOP remains appropriate first-line approach.

Bulky Disease (>10cm)

Consolidation radiation to bulky site post-R-CHOP warrants multidisciplinary discussion.

Specialist Recommendations

Proceed with R-CHOP-21 x 6 cycles as proposed - appropriate for GCB-DLBCL without double-hit features.
Interim PET-CT after cycle 2–3 recommended to assess early response and guide consolidation planning.
Discuss enrollment in POLARIX or similar trials evaluating polatuzumab vedotin-based regimens for high-IPI DLBCL.

Download Full Sample Report (PDF)

PATIENT EXPERIENCES

Clarity When It Matters Most

"The report I received was incredibly detailed but easy to understand. It gave me the confidence to ask my local oncologist about a targeted therapy I didn't know existed. It changed my entire treatment trajectory."

Michael T.

Prostate Cancer Patient

"Living in a rural area, I didn't have access to a major cancer center. Cancer Clarity MD allowed me to get a top-tier specialist's eyes on my complex case without having to travel across the country."

Sarah K.

Breast Cancer Patient

"When my father was diagnosed, we were overwhelmed. The detailed physician report gave our family a roadmap. We finally felt like we understood the options and could have an informed conversation with his oncologist."

David R.

Family Member

GENETIC TESTING CONSULTATION

Understanding Your Genetic Results and What They Mean for Your Family.

Genetic and genomic test results can be complex, emotionally significant, and difficult to interpret without specialist guidance. We offer dedicated consultations to help patients and families navigate these findings with clarity.

Interpreting Your Results

Plain-language explanation of what your genetic or genomic test findings mean - including variants of uncertain significance, hereditary mutations, and somatic tumor markers.

Treatment & Prognosis Implications

How your specific genetic findings affect treatment options, targeted therapy eligibility, immunotherapy response, and long-term prognosis.

Family Testing & Next Steps

Guidance on whether first-degree relatives should pursue genetic testing, what cascade testing involves, and how to communicate findings to family members.

Request a Genetic Consultation

Common Reasons Patients Request a Genetic Consultation

Received hereditary cancer panel results (BRCA1/2, Lynch syndrome, etc.) and need guidance
Tumor genomic profiling (FoundationOne, Tempus, Caris) returned actionable mutations
Uncertain whether a variant of uncertain significance (VUS) is clinically relevant
Want to understand if children or siblings should be tested
Seeking a second opinion on genetic counselor recommendations
Navigating insurance implications of a positive hereditary result

Expert cancer guidance, wherever you are.

A cancer diagnosis often raises important questions

Is my diagnosis accurate?

Are there other treatment options?

Am I eligible for clinical trials?

What does my genomic testing mean?

Specialist-Led. Precisely Organized.

Intelligent Record Organization

Specialist Interpretation

Written Report

If You May Be Eligible, We Connect You.

How the Review Works

Submit Your Records

Case Assignment

Expert Review

Written Report

Video Consultation

Distance Is Not a Barrier.

What You Receive

Clarity When It Matters Most

Michael T.

Sarah K.

David R.

Understanding Your Genetic Results and What They Mean for Your Family.

Interpreting Your Results

Treatment & Prognosis Implications

Family Testing & Next Steps

The Cancer Clarity MD App

Ready for a Specialist's Perspective?